Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,336 result(s) found. Displaying page 1,927 of 2,217.
    «« First « Previous 1923  1924  1925  1926  1927  1928  1929  1930  1931  Next» Last»»
    EudraCT Number: 2016-003673-18 Sponsor Protocol Number: 1062016 Start Date*: Information not available in EudraCT
    Sponsor Name:UZ Brussel
    Full Title: Can we with vitamin D3, improve the innate immune system?
    Medical condition: Immunological problems such as hypogammaglobulinemia with clinical recurrent infections such as sinusitis , pneumonia , otitis , skin infections and gastrointestinal infections.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001424-17 Sponsor Protocol Number: CF113-302 Start Date*: 2021-10-11
    Sponsor Name:Chemo Research S. L.
    Full Title: A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed) LT (Completed) PL (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004444-38 Sponsor Protocol Number: GAIN/GEM/CIS Start Date*: 2019-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det...
    Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028982 Neoplasm biliary tract LLT
    20.0 10042613 - Surgical and medical procedures 10004675 Biliary tract and gallbladder therapeutic procedures HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    21.1 10042613 - Surgical and medical procedures 10061962 Gallbladder operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002476-40 Sponsor Protocol Number: 17-APN-01 Start Date*: 2019-05-07
    Sponsor Name:CHU de Nice
    Full Title: Personalized Medicine for Membranous Nephropathy PMMN
    Medical condition: Idiopathic Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000247-27 Sponsor Protocol Number: ZX-2018-LBT999-DATTEP-3 Start Date*: 2021-03-31
    Sponsor Name:ZIONEXA
    Full Title: Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor.
    Medical condition: Patients suffering from an essential tremor or with Parkinson's disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    20.0 10029205 - Nervous system disorders 10015496 Essential tremor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000597-29 Sponsor Protocol Number: 2017-02-CHRMT Start Date*: 2021-06-02
    Sponsor Name:Centre Hospitalier Régional Metz-Thionville
    Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
    Medical condition: mite allergenic rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004259-35 Sponsor Protocol Number: Ebas0001 Start Date*: 2020-04-28
    Sponsor Name:Rigshospitalet
    Full Title: Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancer
    Medical condition: Male patients with metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006752-14 Sponsor Protocol Number: DualActionWeightLossinIIH1 Start Date*: 2022-08-23
    Sponsor Name:Rigshospitalet, Neurologisk afdeling
    Full Title: Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension
    Medical condition: Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction....
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10004277 Benign intracranial hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001360-39 Sponsor Protocol Number: SU2C-SARC032 Start Date*: 2019-06-24
    Sponsor Name:SARC
    Full Title: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity
    Medical condition: This trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001441-40 Sponsor Protocol Number: SC-Ta1-CF-001 Start Date*: 2019-12-17
    Sponsor Name:SciClone Pharmaceuticals Limited Ltd
    Full Title: A phase II trial to assess the activity and tolerability of Thymosin alpha 1 in Cystic Fibrosis Patients.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004183-21 Sponsor Protocol Number: IP-001-18 Start Date*: 2022-08-19
    Sponsor Name:Iperboreal Pharma Srl
    Full Title: A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis
    Medical condition: End-Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003202-33 Sponsor Protocol Number: ONC -2008-002 Start Date*: 2009-09-15
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome
    Medical condition: POEMS SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002637-11 Sponsor Protocol Number: CBYL719H12301 Start Date*: 2020-03-18
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with adv...
    Medical condition: Advanced triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) NO (Completed) AT (Completed) BG (Completed) SI (Completed) PL (Completed) HR (Completed) GR (Completed) RO (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000108-27 Sponsor Protocol Number: H8A-MC-LZBE Start Date*: 2016-08-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease
    Medical condition: Prodromal Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003229-14 Sponsor Protocol Number: I6T-MC-AMAN Start Date*: 2018-10-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active ...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) LT (Completed) ES (Ongoing) BE (Completed) HU (Completed) AT (Completed) SK (Completed) DK (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000413-36 Sponsor Protocol Number: BGB-3111-306 Start Date*: 2020-02-24
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Wh...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005730-20 Sponsor Protocol Number: G.04.2011 Start Date*: 2011-12-19
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029882 Oat cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005239-53 Sponsor Protocol Number: GO42909 Start Date*: 2021-11-18
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH...
    Medical condition: Relapsed/refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016906 Follicle centre lymphoma, follicular grade I, II, III refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002874-19 Sponsor Protocol Number: 63935937MDS3001 Start Date*: 2015-11-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Sti...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002966-29 Sponsor Protocol Number: CCTL019H2301 Start Date*: 2018-11-22
    Sponsor Name:Novartis Pharma AG
    Full Title: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
    Medical condition: adult patients with aggressive B-cell NHL after failure of rituximab and anthracycline containing first line immunochemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1923  1924  1925  1926  1927  1928  1929  1930  1931  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 09:18:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA